| pubmed-article:21177411 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21177411 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:21177411 | lifeskim:mentions | umls-concept:C1521991 | lld:lifeskim |
| pubmed-article:21177411 | lifeskim:mentions | umls-concept:C1521733 | lld:lifeskim |
| pubmed-article:21177411 | lifeskim:mentions | umls-concept:C1647891 | lld:lifeskim |
| pubmed-article:21177411 | lifeskim:mentions | umls-concept:C0035363 | lld:lifeskim |
| pubmed-article:21177411 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:21177411 | pubmed:dateCreated | 2011-2-17 | lld:pubmed |
| pubmed-article:21177411 | pubmed:abstractText | The retrospective use of prostate cancer tissue is crucial to design tumor marker prognostic studies. We hypothesize that comparison between recent and more historical cases could introduce biases due to stage and grade migration upon time. | lld:pubmed |
| pubmed-article:21177411 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21177411 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21177411 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21177411 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21177411 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21177411 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:21177411 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:21177411 | pubmed:author | pubmed-author:RozetFrançois... | lld:pubmed |
| pubmed-article:21177411 | pubmed:author | pubmed-author:CathelineauXa... | lld:pubmed |
| pubmed-article:21177411 | pubmed:author | pubmed-author:VallancienGuy... | lld:pubmed |
| pubmed-article:21177411 | pubmed:author | pubmed-author:ValidirePierr... | lld:pubmed |
| pubmed-article:21177411 | pubmed:author | pubmed-author:CussenotOlivi... | lld:pubmed |
| pubmed-article:21177411 | pubmed:author | pubmed-author:FromontGaelle... | lld:pubmed |
| pubmed-article:21177411 | pubmed:author | pubmed-author:PrapotnichDom... | lld:pubmed |
| pubmed-article:21177411 | pubmed:copyrightInfo | ©2010 AACR. | lld:pubmed |
| pubmed-article:21177411 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:21177411 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:21177411 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:21177411 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21177411 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21177411 | pubmed:pagination | 836-40 | lld:pubmed |
| pubmed-article:21177411 | pubmed:meshHeading | pubmed-meshheading:21177411... | lld:pubmed |
| pubmed-article:21177411 | pubmed:meshHeading | pubmed-meshheading:21177411... | lld:pubmed |
| pubmed-article:21177411 | pubmed:meshHeading | pubmed-meshheading:21177411... | lld:pubmed |
| pubmed-article:21177411 | pubmed:meshHeading | pubmed-meshheading:21177411... | lld:pubmed |
| pubmed-article:21177411 | pubmed:meshHeading | pubmed-meshheading:21177411... | lld:pubmed |
| pubmed-article:21177411 | pubmed:meshHeading | pubmed-meshheading:21177411... | lld:pubmed |
| pubmed-article:21177411 | pubmed:meshHeading | pubmed-meshheading:21177411... | lld:pubmed |
| pubmed-article:21177411 | pubmed:meshHeading | pubmed-meshheading:21177411... | lld:pubmed |
| pubmed-article:21177411 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21177411 | pubmed:articleTitle | Pathologic reassessment of prostate cancer surgical specimens before molecular retrospective studies. | lld:pubmed |
| pubmed-article:21177411 | pubmed:affiliation | Department of Pathology, CHU/Universite de Poitiers, Poitiers, France. G.fromont@chu-poitiers.fr | lld:pubmed |
| pubmed-article:21177411 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21177411 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
